TG 100572 is primarily used in research and development within the field of pharmacology, particularly as a selective inhibitor of Aurora kinases A and B. It serves as a valuable tool in understanding the mechanisms of action and potential therapeutic applications of kinase-targeting drugs, with a focus on anti-cancer applications. Researchers utilize TG 100572 to explore its effects on Aurora kinases, which play critical roles in cellular processes such as mitosis and cell proliferation. This compound is often employed in preclinical studies to evaluate its efficacy and safety in treating various cancers, including breast, lung, and colorectal cancer, where abnormal kinase activity contributes to tumor growth and metastasis. Additionally, TG 100572 aids in the development of new drug candidates by providing insights into structure-activity relationships and optimizing kinase inhibitor designs. Its application extends to biochemical assays and cellular models, helping to identify promising pathways for therapeutic intervention. However, its use remains in the research and early clinical trial stages, requiring further studies to confirm efficacy and safety in humans.